The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Vα24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages
Open accessAbstract
Tumor infiltration with Valpha24-invariant NKT cells (NKTs) associates with favorable outcome in neuroblastoma and other cancers. Although NKTs can be directly cytotoxic against CD1d+ cells, the majority of human tumors are CD1d-. Therefore, the role of NKTs in cancer remains largely unknown. Here, we demonstrate that CD68+ tumor-associated monocytes/macrophages (TAMs) represented the majority of CD1d-expressing cells in primary human neuroblastomas. TAMs stimulated neuroblastoma growth in human cell lines and their xenografts in NOD/SCID mice via IL-6 production. Indeed, TAMs produced IL-6 in primary tumors and in the BM of patients with metastatic neuroblastoma. Gene expression analysis using TaqMan low-density arrays of 129 primary human neuroblastomas without MYCN amplification revealed that high-level expression of TAM-specific genes (CD14, CD16, IL6, IL6R, and TGFB1) was associated with poor 5-year event-free survival. While NKTs were not cytotoxic against neuroblastoma cells, they effectively killed monocytes pulsed with tumor cell lysate. The killing of monocytes was CD1d restricted because it was inhibited by a CD1d-specific mAb. Cotransfer of human monocytes and NKTs to tumor-bearing NOD/SCID mice decreased monocyte number at the tumor site and suppressed tumor growth compared with mice transferred with monocytes alone. Thus, killing of TAMs reveals what we believe to be a novel mechanism of NKT antitumor activity that relates to the disease outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746
Monocyte and macrophage heterogeneity
Gordon, S., & Taylor, P. R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1733 · Cited by 5,190
The Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1
Ceradini, D. J., Kulkarni, A. R., Callaghan, M. J., Tepper, O. M., Bastidas, N., Kleinman, M. E., Capla, J. M., Galiano, R. D., Levine, J. P., & Gurtner, G. C. (2004) · Nature Medicine · doi:10.1038/nm1075 · Cited by 2,600 · cited 1×
“The same hypoxic areas are a rich source of chemokines such as CCL2 and CXCL12 (54) that promote migration of both TAMs and effector-memory T cells, including NKTs (55).”
BackgroundAmplification of N- myc in Untreated Human Neuroblastomas Correlates with Advanced Disease Stage
Brodeur, G. M., Seeger, R. C., Schwab, M., Varmus, H. E., & Bishop, J. M. (1984) · Science · doi:10.1126/science.6719137 · Cited by 2,262
Self-citationNeuroblastoma: biological insights into a clinical enigma
Brodeur, G. M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1014 · Cited by 2,160
Association of Multiple Copies of the N-myc Oncogene with Rapid Progression of Neuroblastomas
Seeger, R. C., Brodeur, G. M., Sather, H., Dalton, A., Siegel, S. E., Wong, K. Y., & Hammond, D. (1985) · New England Journal of Medicine · doi:10.1056/nejm198510313131802 · Cited by 2,010
Self-citationMatthay, K. K., Villablanca, J. G., Seeger, R. C., Stram, D. O., Harris, R. E., Ramsay, N. K., Swift, P., Shimada, H., Black, C. T., Brodeur, G. M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910143411601 · Cited by 1,898
Self-citationMax: A Helix-Loop-Helix Zipper Protein That Forms a Sequence-Specific DNA-Binding Complex with Myc
Blackwood, E. M., & Eisenman, R. N. (1991) · Science · doi:10.1126/science.2006410 · Cited by 1,697
Cited by
Protective and pathogenic functions of macrophage subsets
Murray, P. J., & Wynn, T. A. (2011) · Nature Reviews Immunology · doi:10.1038/nri3073 · Cited by 5,269
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
Biswas, S. K., & Mantovani, A. (2010) · Nature Immunology · doi:10.1038/ni.1937 · Cited by 3,840
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Macrophages as regulators of tumour immunity and immunotherapy
DeNardo, D. G., & Ruffell, B. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0127-6 · Cited by 2,528
The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy
Bruni, D., Angell, H. K., & Galon, J. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0285-7 · Cited by 1,586
Macrophages, innate immunity and cancer: balance, tolerance, and diversity
Mantovani, A., & Sica, A. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.01.009 · Cited by 1,484
Macrophages and Therapeutic Resistance in Cancer
Ruffell, B., & Coussens, L. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.015 · Cited by 1,474
Matthay, K. K., Maris, J. M., Schleiermacher, G., Nakagawara, A., Mackall, C. L., Diller, L., & Weiss, W. A. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.78 · Cited by 1,419
Targeting natural killer cells and natural killer T cells in cancer
Vivier, E., Ugolini, S., Blaise, D., Chabannon, C., & Brossay, L. (2012) · Nature Reviews Immunology · doi:10.1038/nri3174 · Cited by 850
Lindau, D., Gielen, P., Kroesen, M., Wesseling, P., & Adema, G. J. (2013) · Immunology · doi:10.1111/imm.12036 · Cited by 815
Neuroblastoma: developmental biology, cancer genomics and immunotherapy
Cheung, N.-K. V., & Dyer, M. A. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3526 · Cited by 801
Macrophage-Based Approaches for Cancer Immunotherapy
Anderson, N. R., Minutolo, N. G., Gill, S., & Klichinsky, M. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2990 · Cited by 698
Heczey, A., Louis, C. U., Savoldo, B., Dakhova, O., Durett, A., Grilley, B., Liu, H., Wu, M. F., Mei, Z., Gee, A., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.05.012 · Cited by 535
Craddock, J. A., Lu, A., Bear, A., Pule, M., Brenner, M. K., Rooney, C. M., & Foster, A. E. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181ee6675 · Cited by 513
Du, H., Hirabayashi, K., Ahn, S., Kren, N. P., Montgomery, S. A., Wang, X., Tiruthani, K., Mirlekar, B., Michaud, D., Greene, K., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.01.002 · Cited by 479
Heczey, A., Liu, D., Tian, G., Courtney, A. N., Wei, J., Marinova, E., Gao, X., Guo, L., Yvon, E., Hicks, J., et al. (2014) · Blood · doi:10.1182/blood-2013-11-541235 · Cited by 318
Self-citationUnconventional T Cell Targets for Cancer Immunotherapy
Godfrey, D. I., Le Nours, J., Andrews, D. M., Uldrich, A. P., & Rossjohn, J. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.009 · Cited by 314
Shum, T., Omer, B., Tashiro, H., Kruse, R. L., Wagner, D. L., Parikh, K., Yi, Z., Sauer, T., Liu, D., Parihar, R., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0538 · Cited by 297
Self-citationClinical Significance of Tumor-Associated Inflammatory Cells in Metastatic Neuroblastoma
Asgharzadeh, S., Salo, J. A., Ji, L., Oberthuer, A., Fischer, M., Berthold, F., Hadjidaniel, M., Liu, C. W.-Y., Metelitsa, L. S., Pique-Regi, R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.9169 · Cited by 285
Self-citationAnti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis
Heczey, A., Courtney, A. N., Montalbano, A., Robinson, S., Liu, K., Li, M., Ghatwai, N., Dakhova, O., Liu, B., Raveh-Sadka, T., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1074-2 · Cited by 285
Self-citationAnti‐tumour strategies aiming to target tumour‐associated macrophages
Tang, X., Mo, C., Wang, Y., Wei, D., & Xiao, H. (2013) · Immunology · doi:10.1111/imm.12023 · Cited by 278
Lymphocytes in cancer development: Polarization towards pro-tumor immunity
Ruffell, B., DeNardo, D. G., Affara, N. I., & Coussens, L. M. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.11.002 · Cited by 253
Knox, T., Sahakian, E., Banik, D., Hadley, M., Palmer, E., Noonepalle, S., Kim, J., Powers, J., Gracia-Hernandez, M., Oliveira, V., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-42237-3 · Cited by 170
Paul, S., Chhatar, S., Mishra, A., & Lal, G. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0697-7 · Cited by 150
Circulating and Tumor-Infiltrating Myeloid Cells Predict Survival in Human Pleural Mesothelioma
Burt, B. M., Rodig, S. J., Tilleman, T. R., Elbardissi, A. W., Bueno, R., & Sugarbaker, D. J. (2011) · Cancer · doi:10.1002/cncr.26143 · Cited by 115
Cortesi, F., Delfanti, G., Grilli, A., Calcinotto, A., Gorini, F., Pucci, F., Lucianò, R., Grioni, M., Recchia, A., Benigni, F., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.02.058 · Cited by 100
Silverman, A. M., Nakata, R., Shimada, H., Sposto, R., & DeClerck, Y. A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2165 · Cited by 93
“We reported that the production of Galectin-3 binding protein (Gal-3BP) (also known as 90 kDa Mac-2 binding protein), by neuroblastoma cells was one mechanism that stimulated the expression of IL-6 in BMMSC (21) and in monocytes/macrophages (22).”
BackgroundSelf-citation
Metadata
- Authors
- Song, L., Asgharzadeh, S., Salo, J., Engell, K., Wu, H.-W., Sposto, R., Ara, T., Silverman, A. M., DeClerck, Y. A., Seeger, R. C., & Metelitsa, L. S.
- Venue
- Journal of Clinical Investigation
- Published
- 2009-06-01
- Volume
- 119
- Issue
- 6
- Pages
- 1524-1536
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2034769339
- Cited by
- 342
- References
- 57
- FWCI
- 7.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.